Clinical Trials Browser

Advanced Malignant Solid Neoplasm

NCT00937937 2026-03-20

Dinaciclib in Treating Patients With Stage IV Melanoma

Phase 2 Active not recruiting

72 enrolled 14 charts

Dermatologic

Melanoma

NCT03484520 2022-12-30

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Terminated

48 enrolled

Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT01676753 2022-09-21

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Phase 1 Completed

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02684617 2021-03-01

KEYNOTE-155

Phase 1 Terminated

75 enrolled 17 charts

Lymphoid

rrCLL

NCT01711528 2018-05-11

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1 Completed

41 enrolled

Plasma cell

Multiple Myeloma

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 1 Completed

40 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01515176 2018-03-15

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Phase 1/2 Completed

36 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Phase 1 Completed

81 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01783171 2017-08-22

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

42 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01026324 2017-04-04

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

12 enrolled 9 charts

Dermatologic

Melanoma

NCT01580228 2017-02-23

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Phase 3 Completed

44 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00871546 2015-08-07

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Phase 2 Terminated

8 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00732810 2015-08-05

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Phase 2 Completed

97 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00871663 2015-04-20

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Phase 1 Completed

123 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

NCT01650727 2015-02-10

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Phase 1 Completed

5 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00798213 2015-02-04

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Phase 2 Terminated

29 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01096342 2014-06-18

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

16 enrolled 6 charts

Plasma cell

Multiple Myeloma

Clinical Trials

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Dinaciclib in Treating Patients With Stage IV Melanoma

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

KEYNOTE-155

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Dinaciclib in Treating Patients With Stage III-IV Melanoma

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma